Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pyrimethamine

- PMLiVE

Sarepta soars as FDA clears its muscular dystrophy drug

Analysts anticipate blockbuster status for DMD therapy despite efficacy concerns

Sanofi reception

Sanofi fires off another lawsuit against a Lantus biosimilar

Alleges patent infringement by Merck & Co’s biosimilar version filed in the US last month

- PMLiVE

Snowflakes and fingerprints

No two snowflakes or fingerprints are alike; the same is true of healthcare

UK flag

UK government tables bill on medicine pricing reforms

New scheme proposes single payment mechanism for old and new drugs alike

- PMLiVE

Global pharma market forecast to reach $1.12tr by 2022

Annual growth of 6.3 per cent expected and biologics are set to occupy a stronger position

- PMLiVE

Newron back on track for Xadago approval in US

Italian firm is not required to conduct additional trials for its Parkinson’s disease drug

- PMLiVE

Retrophin rockets away as rare disease trial hits targets

Sparsentan has potential to become a blockbuster FSG drug, according to analysts

- PMLiVE

Merck closes in on first-line NSCLC label for Keytruda in US

Accelerated FDA review could see PD-1 inhibitor approved by the end of the year

Roche Basel Switzerland

Roche’s melanoma combo “too expensive” for NHS use, says NICE

Cost-effectiveness body rejects Cotellic/Zelboraf despite acknowledging survival benefits

- PMLiVE

Allergan CEO takes issue with ‘predatory’ price increases

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

- PMLiVE

Clinton takes aim at pharma pricing once again

Pledges to establish new enforcement powers to address “unjustified price hikes”

Shire Basingstoke

Shire launches dry eye drug Xiidra in US

Sparks rivalry with Allergan’s blockbuster Restasis as first new dry eye treatment in 13 years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links